Friday, 19 Jul 2019


EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid. 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.

Industry Press Releases from EULAR19

Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Below is a collection of the industry press releases detailing the abstracts, authors and presentation times from EULAR 2019.

Preview of EULAR 2019 Abstracts

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

ACR Supports Legislation to Improve Oversight and Transparency of Prior Authorization Use

Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans

RheumNow Podcast – Drug Ad Transparency (6.7.19)

Dr. Jack Cush reviews the news and journal articles of note from this past week on

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis


Analysis of Rheumatoid Arthritis patients enrolled and treated as part of the British Society for Rheumatology Biologics Registry shows that sustained remission or low disease activity state (LDA) on TNF inhibitor treatment is uncommon and that combing methotrexate with an anti-TNF increases the odds of sustained remission/LDA.